HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears by Zielinski, G D et al.
Various molecular and epidemiological data support the notion
that persistent infection with high-risk human papillomavirus
(HPV) is causally related to the development of cervical cancer
and its precursor lesions (Bosch et al, 1995; IARC, 1995; Ho et al,
1998; Nobbenhuis et al, 1999; Walboomers et al, 1999). Further
evidence for this well-established link could come from studies
showing that infection with high-risk HPV precedes development
of cervical premalignant disease in women with cervical cancer.
Most follow-up studies performed so far concerning high-risk
HPV in women with normal cytology have used the development
of precursor lesions of cervical cancer as a surrogate end-point
(Koutsky et al, 1992; Rozendaal et al, 1996; Hopman et al, 2000;
Josefsson et al, 2000; Ylitalo et al, 2000a,b). To our knowledge
only 2 retrospective studies have addressed the issue of high-risk
HPV in normal archival smears of women with cervical cancer
(Walboomers et al, 1995; Wallin et al, 1999). However, upon revi-
sion it appeared that up to 90% of these ‘normal’ archival smears
were false-negative ones. 
Here, we present the results of a retrospective case–control
study using archival smears of women who developed cervical
cancer that were defined in 2 ways: (1) the last smear in the patient
history that was classified as normal according to the original
pathological report, and (2) the last smear in the patient history
that was classified as undisputable normal on the basis of both the
original and a revised cytological assessment. In addition to these
smears and the smears of age-matched control women, all subse-
quent smears of case women and corresponding cancer biopsies
were subjected to high-risk HPV testing by GP5+/6+ PCR-EIA
(Jacobs et al, 1997). 
The major aim of this study was 2-fold: first, to test the potential
value of high-risk HPV testing to signal false-negative cervical
smears in women who develop cervical cancer, and second, to find
out whether high-risk HPV DNA is present in undisputable normal
cervical smears preceding abnormal cytology and whether the
respective HPV type persists until cervical cancer. 
MATERIAL AND METHODS 
Patient selection and study design 
A population-based cervical cancer screening programme started
in 1976 in Zeeland, a district in the Netherlands for which women
between the ages of 35 and 54 years were invited. All smears were
collected and classified in ‘Streeklaboratorium Zeeland’, the only
laboratory of pathology in that area. In this area we started a
case–control study. Women were selected with the aid of the labo-
ratory’s manual registry and the national registration system of
Pathology in the Netherlands (PALGA), which was introduced in
1986. A total of 187 women were registered to have developed
cervical cancer in the period from 1981 to 1998. Of these women,
162 had squamous cell carcinoma and 25 had adenocarcinoma. 
Eligible for this study were women with squamous cell carci-
noma without a history of cervical disease of whom the first
archival smear was registered as normal. Of the 162 women 62
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http://www.bjcancer.comhad a first smear classified as normal. 5 women were excluded for
the following reasons: Absence of archival smears (n = 1), absence
of cervical cancer biopsy (n = 1), and inadequacy of available
archival smears (taken in 1980, 1984 and 1990, respectively) for
DNA detection by PCR (n = 3). 
Consequently, a total of 57 case women ultimately took part in
this study. 31 (54%) of them had their first smear taken within the
screening programme in the period from 1976 to 1996. The
remaining 26 women had their first smear taken for medical
reasons and opportunistic screening. The median age at the time of
diagnosis of cervical cancer was 49 years (range 28–83). Of the 57
women 1 to 8 archival cervical smears were found per case,
resulting in a total of 202 smears. According to the original patho-
logical report 139 of the 202 (69%) smears were classified as cyto-
morphologically normal, of which the large majority was read
before 1988. 5 smears were originally classified as inadequate and
only 58 of the smears taken closer to diagnosis of cervical cancer
were classified as abnormal (mild dyskaryosis or worse). Of the
latter, 31 (53%) smears were read after 1990. 2 case–control
studies were performed: 
(1) For the initial case–control study the last smear in the patient
history that was classified as normal according to the original
pathological report was selected for HPV analysis, and this
smear is indicated as ‘baseline smear’. The median age of the
case women at the time of the baseline smear was 41 years
(range 20–73). 
(2) The second case–control study involved the last smear in
the patient history that was classified as undisputable normal
on the basis of both the original and a revised cytological
assessment. This smear is indicated as ‘revised baseline
smear’. 
In addition, for HPV analysis all available smears subsequent to
the normal smear as well as corresponding formalin-fixed cancer
biopsies were used as well. A flow chart of the whole study design
is given in Figure 1. 
Selection of control women 
For the initial case–control study involving baseline smears 2
control women were selected per case women from women who
participated in the screening programme in the same area in
Zeeland (Figure 1). The control women (n = 114) did not develop
cervical cancer within the same time interval as the case women. If
possible, a normal smear was selected of the control women when
they had the same age as the case women at the time their baseline
smear was taken. If controls of the same age were not available, a
control was selected with an age as close as possible to the age of
the case woman. Optimal selection of controls was limited by the
laboratory’s manual registry, the start of cervical cancer screening
not earlier than 1976, and the law enforcement to keep cervical
smears for 10 years. Therefore, we were unable to use cervical
smears taken after 1986 of women who did not develop cervical
cancer. The median age of the control women was 43 years (range
34–54). This was not significantly different from the age of the
case women (41 years with a range of 20 to 73 years). 
For the second case–control study involving revised baseline
smears, the controls were used of whom the smear remained
normal after revision of cytology (n = 104). 
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57 case women
a total of 202 smears
before cancer diagnosis
63 smears originally
classified as abnormal
139 smears originally
classified as normal
82 smears originally
classified as normal
taken prior to the last normal smear
57 originally normal baseline
smears according to original
report
Case 
control study 1
114 normal smears
according to 
original report
revision
10 abnormal smears
114 age matched controls
HPV testing revision revision
77 abnormal or
inadequate
smears
5 normal
smears
5 normal
smears
48 abnormal
smears
4 inadequate
smears 104 normal smears
Case control study 2
HPV testing
10 women with normal cytology
HPV testing follow-up smears 
with abnormal cytology and
corresponding biopsies
Figure 1 Flow chart of cases/controls and study design 400 GD Zielinski et al 
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Revision of cytology and histology and quality of the
smears 
All originally normal smears were revised blindly, by mixing
smears of cases and controls randomly, according to the KOPAC
classification as described before (Vooijs, 1987). Briefly: Pap 0 is
inadequate material for review, Pap 1 is normal cytology, Pap 2
is very mild dyskaryosis, Pap 3a1 is mild dyskaryosis, Pap 3a2 is
moderate dyskaryosis, Pap 3b is severe dyskaryosis, Pap 4 is suspect
for carcinoma in situ and Pap 5 is suspect for invasive cancer.
Since the detection of HPV DNA may depend on the number of
epithelial cells, this number was crudely estimated by microscop-
ical assessment of the proportion of epithelial cells in several
representative microscopic fields using a point-counting raster and
multiplying this value with the number of cells in the smear. The
latter was estimated on the basis of a comparison with a more or
less ideal smear containing about 2 million cells. 
The cervical cancer biopsy specimens were histopathologically
reviewed to confirm the diagnosis. 
DNA extraction and HPV detection by PCR 
Archival smears were processed using the High Pure PCR
Template Preparation (HPPTP) extraction assay, as described
previously (Jacobs et al, 2000). HPV detection in the smears of
cases and controls was blinded by mixing them at random. 
Of the formalin-fixed biopsies five to ten 5 mm thick sections of
the cancer biopsies were cut, according to the sandwich-method.
This method allows a histopathological assessment to ascertain
that tissue sections processed for HPV detection contain cancer
cells (Walboomers et al, 1997). Further processing was as
described before (Jacobs et al, 1997). 
A  b-globin PCR generating a 209 base pair product was
performed on all smears and cancer biopsies, to determine DNA
integrity of the samples (De Roda Husman et al, 1994). If samples
of the cancer biopsies were b-globin negative, the HPPTP extrac-
tion assay was used to clear the DNA from possible PCR
inhibitors. Only samples that were ß-globin PCR positive were
subjected to high risk HPV analysis. High-risk HPV detection was
performed by GP5+/6+ PCR EIA as described before (Jacobs et al,
1997, 2000; Walboomers et al, 1997). 
High-risk HPV genotypes were first determined as a group
using a cocktail of HPV type-specific oligoprobes, followed by
individual typing for 14 high-risk HPV types (16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 66 and 68). The cut-off for HPV posi-
tivity was set to 3 times the average optical density of PCR nega-
tive controls (Jacobs et al, 1997). 
For HPV detection in the corresponding biopsy specimen the
GP5+/6+ PCR EIA was supplemented with E7 region specific
PCR assays as described before, since in cancer biopsies the L1
based GP5+/6+ assay may fail to reveal the presence of HPV DNA
due to possible integration events of the viral genome, which
occurs in about 3% of the cases (Walboomers et al, 1999). 
Statistical analysis 
The odds ratios (OR) and their confidence intervals were estimated
by logistic regression analysis. Differences between the investi-
gated continuous variables were tested using the Mann–Whitney U
test or Kruskal–Wallis test and between categorical variables using
the Fisher test. All reported P values were 2-sided. To estimate the
time-interval of infection with high-risk HPV to diagnosis of
cervical cancer, the smears taken 0.5 years or less before diagnosis
of cervical cancer, were excluded. 
RESULTS 
HPV detection in baseline smears of cases and normal
smears of controls 
High-risk HPV DNA was detected in 37 of the 57 (65%) baseline
smears of the case women (Table 1). HPV 16, 18 and HPV 31
DNA were present in 29, 3 and 3 baseline smears, respectively,
and HPV 33 and HPV 45 were each present in 1 of the baseline
smears. In contrast, high-risk HPV DNA was detectable in only 7
of the 114 (6%) smears analysed of the control women. In these
smears HPV 16, 18 and HPV 31 were each found twice and HPV
45 once. The prevalence of high-risk HPV DNA was significantly
less in the control group than in the case group (P < 0.001, Fisher
test). The crude odds ratio for high-risk HPV DNA in smears clas-
sified as normal according to the original pathological report to
predict development of cervical squamous cell carcinoma was 28
(95% CI 11–72; Table 1). 
HPV detection in subsequent smears and biopsies of
case women 
Of the 57 case women 52 ß-globin PCR positive abnormal smears
were available that were taken after the baseline smears but prior
to diagnosis of cervical cancer. 38 (73%) of them were high-risk
HPV positive. In 52 of the 57 (91%) women the corresponding
cervical carcinoma biopsies, revealed high-risk HPV positivity. A
total of 41 (72%) women had high-risk HPV in the baseline and/or
subsequent smears and corresponding biopsies (Table 2). In all
HPV positive cases, the same HPV type was present in the base-
line smears, subsequent smears and corresponding biopsies that
scored positive by high-risk HPV PCR. Based on HPV status in
smears and cancer biopsy, women could be placed into 4 groups.
The first group (n = 33) consisted of women with both baseline,
follow-up smears (when available) and corresponding cervical
cancer biopsy consistently HPV positive. The second group (n = 8)
Table 1 High risk HPV in baseline and control smears, age of women and storage time 
Number of case women Number of control women Odds ratio 
HPV+ (%) 37 (65%) 7 (6%) 28 (95% Cl 11–72)a
HPV– (%) 20 (36%) 107 (94%) 1 
Median age in years (range) 41 (20–73) 43 (34–54) 
Median storage time in years (range) 16.5 (0.9–35.0) 20.9 (14.5–23.1) 
aThe crude odds ratio for high-risk HPV DNA in baseline smears classified as normal according to the original pathological report to
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included women with follow-up smears in which the presence of
HPV fluctuated in the smears, but of whom the cancer biopsy was
HPV positive. 5 of these women had 2 smears of whom 3 had a
first smear negative for high-risk HPV and a second smear and
corresponding cancer biopsy positive for high-risk HPV. The other
2 case women had high-risk HPV detectable in the first smear and
corresponding cancer biopsy, but not in the second smear. 2 other
case women of this group had a first smear and corresponding
cancer biopsy positive for high-risk HPV DNA, but their second
and third smear were negative. The last case woman within this
group had a first and third smear, and corresponding cancer biopsy
positive for high-risk HPV DNA, whereas the second, fourth and
fifth smear were high-risk HPV negative. The third group (n = 11)
included women with all smears being HPV negative, but a cancer
biopsy that was positive for high-risk HPV. The fourth group 
(n = 5) comprised women of whom both smears and cancer biop-
sies were negative for high-risk HPV. Although the prevalence of
high-risk HPV in the follow-up smears tended to be highest in the
smears taken closest to diagnosis of cervical cancer (76% HPV posi-
tivity in smears taken less then 3 years prior to cancer diagnosis) the
difference with smears taken at an earlier time point was not
significant (KW P = 0.316, Table 3). 
Abnormal cytology after revision of the baseline
smears in relation to presence of high-risk HPV 
All baseline smears and smears of control women were revised
according to the KOPAC-B classification currently used in the
Netherlands (Table 4). The baseline smears of 48 case women
(84%) were reclassified as abnormal (Pap 2 or worse), 4 (7%)
were inadequate for cytology and only 5 (9%) remained normal.
Of the 48 revised abnormal baseline smears of the case women 33
(69%) revealed the presence of high-risk HPV. The median time to
diagnosis of cervical cancer was 8.3 years (0.5–19.2 years) for the
revised abnormal baseline smears. Of the 24 smears reclassified as
moderate dyskaryosis or worse 21 (88%) were HPV positive. The 3
smears in this group in which no HPV DNA could be detected
included 2 of the 10 Pap 3a2 (moderate dyskaryosis) and 1 of the 12
(8%) Pap 3b (severe dyskaryosis) smears. In contrast, only 10 of the
114 (9%) smears of the control women were revised as abnormal; 8
Table 2 Results of HPV detection in baseline and follow-up smears of 57 case women 
Number of smears  Number of case women 
of case women
(number of women) cxcaa HPV+ cxca HPV– Total number of smears 
(number of HPV + smears) 
All smears HPV+ Smears HPV+ and HPV– All smears HPV– All smears HPV– 
1 (28) 16 9 3 28 (16) 
2 (17) 9 5 2 1 34 (23) 
3 (7) 4 2 1 21 (14) 
4 (2) 2 8 (8) 
5 (1) 1 5 (2) 
6 (1) 1 6 (6) 
7 (1) 1 7 (7) 
(57) 33 (58%) 8 (14%) 11 (19%) 5 (9%) 109 (76 HPV+, 70%) 
acxca = cervical carcinoma. 
Table 3 HPV detection in baseline and follow-up smears of case women stratified for years before diagnosis of
cervical cancer 
Years before diagnosis of cervical cancer HPV– smears HPV+ smears Total number of smears 
0–3 12 (24%) 38 (76%) 50 
4–6 7 (37%) 12 (63%) 19 
7–20 14 (34%) 27 (66%) 41 
Total 33 (30%) 76 (70%) 109 
Table 4 Revision of baseline smears in relation to HPV status and number of epithelial cells 
Revision according to KOPAC-B Number of case women  %HPV+ (n HPV+) Number of epithelial cells (range) ´ 104
HPV+ HPV–a
Inadequate (Pap 0) 4 (7%) 0% (0) 5.9 (0.9–36) 
Normal (Pap 1) 5 (9%) 80% (4) 24.9 (2.5–115.2) 5.4 
Very mild dyskaryosis (Pap 2) 19 (33%) 58% (11)  20.0 (4.5–96) 20.5 (20–90) 
Mild dyskaryosis (Pap 3a1) 5 (9%) 20% (1) 57.8 35.2 (12.1–78.4) 
Moderate dyskaryosis (Pap 3a2) 10 (17%) 80% (8)  75.8 (15.0–99.2) 10.5 (8.4–12.6) 
Severe dyskaryosis (Pap 3b) 12 (21%) 92% (11)  38 (6.3–160) 9.6 
Suspect for carcinoma in situ (Pap 4) 1 (2%) 100% (1) 49 
Suspect for carcinoma (Pap 5) 1 (2%) 100% (1)  60 
Total 57 65% (37) 40 (2.5–160) 12.4 (0.9–90) 
aThe number of epithelial cells in high-risk HPV negative smears was significantly lower than in high-risk HPV positive cervical smears (KW P = 0.018). 402 GD Zielinski et al 
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of them were reclassified as very mild dyskaryosis (Pap 2), 1 as
mild dyskaryosis (Pap 3a1) and 1 as severe dyskaryosis (Pap 3b). 
HPV presence in revised abnormal smears in relation to
the storage time and the number of epithelial cells 
In order to find out what phenomenon may underlie the non-
detection of HPV in the 15 HPV negative, revised abnormal base-
line smears the storage time and number of epithelial cells were
analysed in relation to HPV detection (Table 4). The number of
epithelial cells was significantly lower in the high-risk HPV-nega-
tive (median 1.2 ´ 105, range 9.0 ´ 103–9.0 ´ 105) compared to
high-risk HPV-positive baseline smears (median 4.0 ´ 105, range
3 ´ 104–1.6 ´ 106; KW P = 0.018, Table 4). No significant differ-
ences in storage time of HPV negative (20.5 years, range 7.1–24.7
years) versus HPV positive (19.6 years, range 9.4–35 years) smears
was evident (P = 0.54. Mann–Whithey). Also the median duration
of taking the abnormal smears to diagnosis of cervical cancer did
not differ significantly between HPV negative (9.0 years, range:
0.5–19.0 years) and HPV positive (8.0, range 0.5–19.2 years)
abnormal baseline smears (P = 0.17, Mann–Whitney). 
HPV detection in undisputable normal baseline smears
after revision 
High-risk HPV was present in the baseline smear of 4 (80%) of the
5 case women of whom this smear remained normal after revision.
5 other case women had a smear that was revised as normal, taken
prior to the baseline smear previously defined. High-risk HPV
DNA was detected in 3 of these smears. Therefore, the total number
of case women that ultimately remained with an undisputable
normal baseline smear after revision was 10, 7 (70%) of which
revealed high-risk HPV positivity. 7 (7%) of 104 revised normal
smears of the controls were HPV positive. The crude odds ratio for
high-risk HPV DNA detection in revised baseline smears to
predict development of carcinoma was 32 (95% Cl 6.8–153; Table
5). The median duration to diagnosis of cervical cancer for the
HPV positive revised baseline smears was 10.7 years (range
9.6–17.4). This was not markedly different for revised baseline
smears that were HPV negative (10.7 years, range 8.6–15.2 years).
However, the high-risk HPV-negative baseline smears revealed a
lower number of epithelial cells than the high-risk HPV positive
smears (median 6.4 ´ 104, range 5.4 ´ 104–12.8 ´ 104 and median
16.2 ´ 104, range 2.6 ´ 104–1.2 ´ 105, respectively). 
High-risk HPV was furthermore present in 1 or more of the
follow-up smears of 8 women (Table 6). Of all women the corre-
sponding cervical cancer biopsy was HPV positive. Typing
revealed HPV 16 in 6, HPV 18 in 3 and HPV 31 in 1 of the carci-
nomas. The same HPV types were present in corresponding HPV
positive smears. 
Based on HPV status in smears and cancer biopsy, women could
be placed into 3 groups. The first group (n = 5) consisted of women
with both baseline, follow-up smears (when available) and corre-
sponding cervical cancer biopsy consistently HPV positive. The
second group (n = 3) comprised women with follow-up smears in
which the presence of HPV fluctuated and of whom the cancer
biopsy was HPV positive. One of these case women had a high-risk
HPV negative normal smear and a subsequent abnormal smear that
was HPV positive 5.7 years before diagnosis of cervical cancer
(Table 6, case women 81). The third group (n = 2) comprised women
with HPV negative smears but a cancer biopsy that was positive for
high-risk HPV (Table 6, case woman 45 and case woman 87). 
Table 6 Characteristics of case women with revised baseline smears 
Case HPV type in revised baseline smear Years before cervical cancer HPV positive/total no.of smears HPV type in cancer biopsy 
8 31 5.8 2/2 31 
26 16 9.6 4/4 16 
28 16 10.8 3/3 16 
45 – 15.2 0/2 18 
67 16 17.4 1/1 16 
72a 18 10.8 6/9 18 
81 – 8.6 1/5 18 
83b 16 9.7 3/4 16 
87 – 10.7 0/2 16 
88c 16 10.3 4/4 16 
Total 24/36 (64%) 10/10 
aCase 72 had 1 cytomorphologically normal smear that was HPV negative 14.8 years before diagnosis of cervical cancer, with a storage time of 22.5 years. 
bCase 83 had 2 cytomorphologically normal smears of which one was HPV positive 11.7 years before diagnosis of cervical cancer, with a storage time of 15.3
years and the other taken 14.3 years before diagnosis of cervical cancer, with a storage time of 18.0 years was HPV negative. cCase 88 had 1
cytomorphologically normal smear that was HPV positive 13.8 years before diagnosis of cervical cancer, with a storage time of 14.3 years. 
Table 5 High risk HPV in revised baseline and control smears 
Number of case women (%) Number of control women (%)  Odds ratio 
HPV+ 7 (70%) 7 (7%) 32 (95% Cl 6.8–153)a
HPV– 3 (30%) 97 (93%) 1 
Total 10 104 
aThe crude odds ratio for high-risk HPV DNA in smears revised as normal according to the KOPAC-B
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Of 3 case women normal smears were available that preceded
the HPV positive revised baseline smear. In one of them that smear
was HPV positive 13.8 years before diagnosis of cervical cancer
(Table 6, case woman 88). Another had 2 preceding normal
smears, one of which was HPV positive 11.7 years before diag-
nosis of cervical cancer and another taken 14.3 years before cancer
diagnosis was HPV negative (Table 6, case woman 83). A third
woman had an earlier HPV negative normal smear taken 14.8
years before cancer diagnosis (Table 6, case woman 72). 
DISCUSSION 
This retrospective population based case–control study revealed
that high-risk HPV testing signals 69% of the false negative
archival smears (33 of 48 revised abnormal baseline smears were
HPV positive) of women who developed cervical cancer. High-
risk HPV DNA was also detectable in undisputable normal smears
preceding cervical cancer in 7 of the 10 women analysed. The
same HPV type was detected in revised baseline smears, subse-
quent smears and corresponding biopsies that were HPV positive.
This does not only provide further evidence that high-risk HPV
precedes the development of premalignant disease leading to
cervical cancer, but also supports the notion that viral persistence
is essential in this process. Furthermore, we found that high-risk
HPV positivity in revised normal cervical smears was strongly
associated with cervical cancer development (OR 32, 95% CI
6.8–153). However, it should be kept in mind that this figure may
be overestimated since a subset of controls used in this analyses
was of older age than the corresponding cases. It is well known
that the HPV prevalence is higher among younger women
(Melkert et al, 1993). 
The clinical implications of our findings are 2-fold: First, HPV
testing may serve as a quality control for cytology. This is
supported by the recent finding that revision of HPV-positive
normal smears of a screening population yielded abnormal smears
in 5% to 7% of the cases (Meijer et al, 1997). Second, HPV testing
allows the recognition of women at risk prior to the manifestation
of abnormal cytology. In the 7 women with HPV positive undis-
putable normal baseline smears, the median duration until the
diagnosis of cervical cancer was 10.7 years (8.6–15), which was at
least 2 years longer than that of the manifestation of abnormal
cytology. This finding suggests that the current time-interval to the
next screening round (which is 5 years in the Netherlands) for
women with HPV-negative normal cytology in cervical cancer
screening programmes could be prolonged. However, the number
of women studied for assessment of the time interval between the
normal smear and cervical cancer should be increased before an
accurate statement about this time interval can be given. 
Similar to other studies, a considerable proportion of baseline
smears of case women that were originally classified as normal,
were reclassified as abnormal after revision (Walboomers et al,
1995; Wallin et al, 1999). In contrast, the far majority (95%) of
smears of the control women remained normal after revision.
Reasons for previous false-negative smears, of which the far
majority was read before 1988 when the KOPAC classification
was introduced, may include technical failures like screening
fatigue and very few dyskaryotic cells present in the smears. In
addition, the imperfection of former cytology, i.e. the ignorance of
tissue fragments, may, in part, be responsible. Since former
training programmes concentrated almost exclusively on cytology
of dissociated cells, no attention was paid to the identification of
tissue fragments (Robertson and Woodend, 1993). It is noteworthy
that we more than incidently observed tissue fragments in the
smears that were revised as abnormal. In conclusion, it is likely
that the use of current criteria of cytology would have yielded
fewer false negative smears among the case women in this study. 
Although the great majority of false-negative baseline smears
were positive for high-risk HPV still 15 of them scored HPV nega-
tive. However, it is of note that we found that the number 
of epithelial cells was significantly lower in the HPV-negative
compared to the positive baseline smears. Moreover, the extraction
method we used, yields at maximum amplifiable DNA of 40% 
of the total DNA content of a given smear (Jacobs et al, 
2000). Wallin et al (1999) attributed underestimation of HPV posi-
tivity in archival smears of cancer patients to storage time, and the
fact that HPV detection was performed on archival smears instead
of fresh samples (Cuzick et al, 2000). Taken together, it is likely
that factors like low number of epithelial cells, relatively low
yields of extracted DNA and reduced DNA quality of stored
smears alone or in combination, may contribute to an underestima-
tion of HPV presence in archival smears. Therefore, the analysis
of fresh rather than archival smears probably would have signalled
even more cytomorphologically false negative cases (Cuzick et al,
2000). 
In our previous retrospective study on a smaller series of
archival smears of case women from another area in the
Netherlands high-risk HPV DNA was detected in a higher (i.e.
89%) percentage of baseline smears (Walboomers et al, 1995).
However, after revision all adequate smears in that study were
reclassified as severe dyskaryosis or worse. In this study, the base-
line smears that were revised as severe dysplasia or worse also
revealed a higher HPV prevalence (Table 4). In contrast, the
percentage of HPV positive baseline smears was markedly lower
(i.e. about 30%) in a study of Wallin et al (1999). Here, also the
number of smears that were reclassified as dyskaryotic after revi-
sion was lower. Although technical differences, such as the use of
different DNA isolation procedures may partially underlie the
different prevalence rates, these findings are in favour of the idea
that differences in HPV prevalence in smears preceding cervical
cancer can also be due to differences in the proportion of dyskary-
otic smears (Walboomers et al, 1995). 
Another finding was that the HPV prevalence in the cervical
carcinomas (91%) in this study was lower than previously reported
for a worldwide study, in which 4 different HPV primer sets were
used (Bosch et al, 1995; Walboomers et al, 1999). However, it
should be kept in mind that our study is based on the analysis of
samples that were not optimal, i.e. archival, formalin-fixed tissue
samples that had been stored for quite some time. 
In conclusion, this study unambiguously demonstrated the pres-
ence of the same HPV type in undisputable normal and subsequent
abnormal smears until diagnosis of cervical cancer, and thus
showed that high-risk HPV detection precedes the development of
abnormal cytology. Since the duration to cervical cancer is about
10 years for an undisputable normal smear these data suggest that
the time interval between 2 screening rounds can be increased
from 5 years (as it is now in The Netherlands) to 8–10 years.
Furthermore, since in this study high-risk HPV testing signalled
69% of the abnormal smears originally misclassified as normal, of
the women who developed cervical cancer, we suggest to rescreen
all high-risk HPV-positive cytomorphologically normal smears. In
that case, HPV testing provides a safety net for false negative
smears of women who are at risk of cervical cancer. 404 GD Zielinski et al 
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